vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1468Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ АДАЛИМУМАБА У БОЛЬНОЙ ЮНОШЕСКИМ ПОЛИАРТРИТОМ С ПОРАЖЕНИЕМ ГЛАЗEXPERIENCE OF TREATMENT OF JUVENILE POLYARTHRITIS WITH EYES LESION WITH ADALIMUMABЛисицинА.О.LisitsinA.O.АлексееваЕ.И.AlexeevaE.I.БзароваТ.М.BzarovaT.M.ВалиеваС.И.ValievaS.I.ЧомахидзеА.М.ChomakhidzeA.M.ИсаеваК.Б.IsaevaK.B.ЧистяковаЕ.Г.ChistyakovaE.G.ДенисоваР.В.DenisovaR.V.ГудковаЕ.Ю.GudkovaE.Yu.КарагулянН.А.KaragulyanN.A.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children's Health, Russian Academy of Medical Sciences, MoscowRussian Federation20080511201575Вопросы современной педиатрии115120Copyright © Лисицин А., Алексеева Е., Бзарова Т., Валиева С., Чомахидзе А., Исаева К., Чистякова Е., Денисова Р., Гудкова Е., Карагулян Н., 20082008Лисицин А., Алексеева Е., Бзарова Т., Валиева С., Чомахидзе А., Исаева К., Чистякова Е., Денисова Р., Гудкова Е., Карагулян Н.Lisitsin A., Alexeeva E., Bzarova T., Valieva S., Chomakhidze A., Isaeva K., Chistyakova E., Denisova R., Gudkova E., Karagulyan N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1468ReferencesCassidy J., Petty R., eds. Textbook of paediatric rheumatology. 2nd end. New York: Churchill Livigstone. 2002.Cassidy J., Petty R., eds. Textbook of paediatric rheumatology. 2nd end. New York: Churchill Livigstone. 2002.Benеzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89 (4): 444–448.Benеzra D., Cohen E., Maftzir G. Uveitis in children and adolescents. Br. J. Ophthalmol. 2006; 89 (4): 444–448.Foster C. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Current. Opin. Ophthalmol. 2003; 14 (6): 395–398.Foster C. Diagnosis and treatment of juvenile idiopathic arthritis associated uveitis. Current. Opin. Ophthalmol. 2003; 14 (6): 395–398.Arend W., Dayer J. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 1995; 38 (2): 151–160.Arend W., Dayer J. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 1995; 38 (2): 151–160.Beutler B. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (57): 16–21.Beutler B. The role of tumor necrosis factor in health and disease. J. Rheumatol. 1999; 26 (57): 16–21.Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. М.: Медицина. 2000. 430 с.Хаитов Р.М., Игнатьева Г.А., Сидорович И.Г. Иммунология. М.: Медицина. 2000. 430 с.Danks L., Sabokbar A., Gundle R. et al. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann. Rheum. Dis. 2002; 61 (10): 916–921.Danks L., Sabokbar A., Gundle R. et al. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann. Rheum. Dis. 2002; 61 (10): 916–921.Barrera P., Boerbooms A.M., Janssen E.M. et al. Circulating soluble tumor necrosis factor receptors, interleukin–2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993; 36 (8): 1070–1079.Barrera P., Boerbooms A.M., Janssen E.M. et al. Circulating soluble tumor necrosis factor receptors, interleukin–2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993; 36 (8): 1070–1079.Kalden J. Emerging role of antitumor necrosis factor therapy in rheumatic disease. Arthritis Research. 2002; 4 (Suppl. 2): 34–40.Kalden J. Emerging role of antitumor necrosis factor therapy in rheumatic disease. Arthritis Research. 2002; 4 (Suppl. 2): 34–40.Насонов Е.Л. Фактор некроза опухоли–α — новая мишень для противовоспалительной терапии ревматоидного артрита. Клиническая фармакология и терапия. 2001; 1: 64–70.Насонов Е.Л. Фактор некроза опухоли–α — новая мишень для противовоспалительной терапии ревматоидного артрита. Клиническая фармакология и терапия. 2001; 1: 64–70.Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Annals of Rheumatic Disease. 2003; 62 (3): 245–247.Lahdenne P., Vahasalo P., Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Annals of Rheumatic Disease. 2003; 62 (3): 245–247.Алексеева Е.И., Алексеева А.М., Бзарова Т.М. и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (2): 20.Алексеева Е.И., Алексеева А.М., Бзарова Т.М. и др. Эффективность лечения инфликсимабом резистентных форм ювенильного ревматоидного артрита. Вопросы современной педиатрии. 2006; 5 (2): 20.Насонов Е.Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли. РМЖ. 2001; 9: 7–9.Насонов Е.Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли. РМЖ. 2001; 9: 7–9.Furst D., Schiff M., Fleischmann R. et al. Adahmumab, a fully human anti–tumor necrosis factor ᾳ monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adahmumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30 (12): 2563–2571.Furst D., Schiff M., Fleischmann R. et al. Adahmumab, a fully human anti–tumor necrosis factor ᾳ monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis results of STAR (Safety Trial of Adahmumab in Rheumatoid Arthritis). J. Rheumatol. 2003; 30 (12): 2563–2571.Keystone E., Kavanaugh A., Sharp J. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004; 50 (5): 1400–1411.Keystone E., Kavanaugh A., Sharp J. et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004; 50 (5): 1400–1411.Mease P., Gladman D., Ritchhn C. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52 (10): 3279–3289.Mease P., Gladman D., Ritchhn C. et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52 (10): 3279–3289.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of juvenile idiopathic arthritis associated uveitis – a pilot study. 8th Annual European League Against Rheumatism. Barcelona. 2007. Abstract THU0483.Tynjala P., Kotaniemi K., Lindahl P. et al. Adalimumab in the treatment of juvenile idiopathic arthritis associated uveitis – a pilot study. 8th Annual European League Against Rheumatism. Barcelona. 2007. Abstract THU0483.Vazquez-Cobian L.B., Flynn T., Lehman T.J. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149 (4): 572–575.Vazquez-Cobian L.B., Flynn T., Lehman T.J. Adalimumab therapy for childhood uveitis. J. Pediatr. 2006; 149 (4): 572–575.Dana M., Merayo–Lloves J., Schaumberg D., Foster C.S. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997; 104 (2): 236–244.Dana M., Merayo–Lloves J., Schaumberg D., Foster C.S. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997; 104 (2): 236–244.
The authors declare that there are no conflicts of interest present.